Cumberland Pharmaceuticals Inc. (CPIX) Key Metrics
CPIX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $107.6M
- Enterprise value
- $105.4M
- P/E (TTM)
- —
- Forward P/E
- 50.0
- PEG ratio
- 1.67
- Price / sales
- 2.4 10-yr median 1.6
- Price / book
- 6.0 10-yr median 1.5
- EV / EBITDA
- 40.9 10-yr median 102.0
- Dividend yield
- —
- Beta
- 0.04
CPIX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCPIX valuation Price multiples at each fiscal year-end price.
CPIX returns How much profit the business earns on the capital it uses.
CPIX per-share figures Results divided by the shares outstanding at year-end.
CPIX financial health Debt, liquidity and how easily interest is covered.
CPIX efficiency & capital use Working capital cycle and where the cash goes.
CPIX valuation history
CPIX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CPIX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CPIX cash returned to shareholders
CPIX price vs earnings per share
CPIX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $59.5M | $33.3M | $25.6M | $32.8M | $69.6M | $44.7M | $79.3M | $94.2M | $117.1M | $89.3M |
| Enterprise value | $58.3M | $35.9M | $25.7M | $34.0M | $58.6M | $39.2M | $72.6M | $77.9M | $76.8M | $43.3M |
| Price / sales | 1.3 | 0.9 | 0.6 | 0.8 | 1.9 | 1.2 | 2.3 | 2.3 | 2.8 | 2.7 |
| Price / book | 2.4 | 1.5 | 0.9 | 0.9 | 1.6 | 1.0 | 1.6 | 1.7 | 1.8 | 1.2 |
| Price / free cash flow | 12.3 | — | 4.5 | 5.1 | 11.6 | 13.5 | 28.2 | — | — | — |
| Price / operating cash flow | 12.1 | — | 4.2 | 3.9 | 11.0 | 8.3 | 25.9 | 30.2 | — | 156.8 |
| EV / sales | 1.3 | 0.9 | 0.7 | 0.8 | 1.6 | 1.0 | 2.1 | 1.9 | 1.9 | 1.3 |
| EV / EBITDA | 19.7 | 197.0 | 167.8 | 102.0 | — | — | — | — | — | 37.0 |
| EV / free cash flow | 12.1 | — | 4.6 | 5.3 | 9.8 | 11.9 | 25.8 | — | — | — |
| Earnings yield | −4.8% | −19.4% | −24.5% | −17.0% | −5.0% | −7.5% | −4.5% | −7.4% | −6.8% | −1.1% |
| Free cash flow yield | 8.1% | −2.4% | 22.0% | 19.5% | 8.6% | 7.4% | 3.5% | −1.2% | −1.7% | −1.7% |
| Dividend yield | — | — | — | — | — | 0.3% | — | 59.5% | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 0.4% | 1.7% | 2.9% | 3.2% | 2.0% | 4.4% | 4.4% | 62.5% | 3.2% | 2.8% |
| Share price at fiscal year-end | $3.98 | $2.37 | $1.79 | $2.25 | $4.67 | $2.95 | $5.15 | $6.03 | $7.36 | $5.50 |
| Per share | ||||||||||
| Revenue per share | $2.98 | $2.69 | $2.77 | $2.88 | $2.41 | $2.47 | $2.23 | $2.61 | $2.59 | $2.03 |
| Earnings per share | −$0.19 | −$0.46 | −$0.44 | −$0.38 | −$0.24 | −$0.22 | −$0.23 | −$0.45 | −$0.50 | −$0.06 |
| Operating cash flow per share | $0.33 | −$0.04 | $0.43 | $0.58 | $0.43 | $0.36 | $0.20 | $0.20 | −$0.04 | $0.04 |
| Free cash flow per share | $0.32 | −$0.06 | $0.39 | $0.44 | $0.40 | $0.22 | $0.18 | −$0.07 | −$0.13 | −$0.10 |
| Cash per share | $0.77 | $1.28 | $1.28 | $1.36 | $1.81 | $1.63 | $1.83 | $2.32 | $3.15 | $3.09 |
| Book value per share | $1.66 | $1.63 | $2.07 | $2.49 | $2.87 | $3.10 | $3.32 | $3.58 | $4.02 | $4.50 |
| Tangible book value per share | $0.66 | $0.28 | $0.43 | $0.33 | $1.21 | $1.19 | $1.25 | $1.37 | $2.67 | $3.14 |
| Dividends per share | — | — | — | — | — | $0.01 | — | $3.59 | $0.00 | $0.00 |
| Capex per share | $0.01 | $0.01 | $0.03 | $0.14 | $0.02 | $0.14 | $0.02 | $0.27 | $0.09 | $0.13 |
| Debt per share | $0.68 | $1.46 | $1.29 | $1.44 | $1.08 | $1.27 | $1.40 | $1.28 | $0.62 | $0.25 |
| Shares outstanding | 15.0M | 14.1M | 14.3M | 14.6M | 14.9M | 15.2M | 15.4M | 15.6M | 15.9M | 16.2M |
| Change in shares outstanding | +6.4% | −1.7% | −1.8% | −2.3% | −1.7% | −1.5% | −1.4% | −1.9% | −2.0% | −5.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −11.9% | −24.7% | −19.1% | −14.1% | −7.8% | −6.8% | −6.6% | −11.6% | −11.6% | −1.3% |
| Return on invested capital (ROIC) | −9.0% | −18.4% | −22.5% | −13.0% | −16.5% | −11.7% | −17.5% | −18.5% | −12.7% | −4.3% |
| Return on assets (ROA) | −3.7% | −8.2% | −7.2% | −6.3% | −3.9% | −3.3% | −3.3% | −6.8% | −8.5% | −1.0% |
| Return on tangible assets | −4.6% | −11.4% | −10.8% | −9.1% | −5.9% | −4.9% | −4.9% | −8.9% | −11.1% | −1.3% |
| Free cash flow margin | 10.9% | −2.1% | 14.3% | 15.2% | 16.6% | 8.8% | 8.2% | −2.9% | −5.0% | −4.7% |
| Financial health | ||||||||||
| Total debt | $10.2M | $20.6M | $18.4M | $21.0M | $16.1M | $19.3M | $21.5M | $20.0M | $9.8M | $4.1M |
| Cash & short-term investments | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M | $24.8M | $28.2M | $36.2M | $50.1M | $50.1M |
| Net debt | −$1.3M | $2.6M | $106,859 | $1.2M | −$11.0M | −$5.5M | −$6.7M | −$16.2M | −$40.3M | −$46.0M |
| Debt / equity | 0.41 | 0.90 | 0.62 | 0.58 | 0.38 | 0.41 | 0.42 | 0.36 | 0.15 | 0.06 |
| Debt / assets | 0.13 | 0.27 | 0.23 | 0.23 | 0.19 | 0.20 | 0.21 | 0.18 | 0.11 | 0.04 |
| Net debt / EBITDA | −0.43 | 14.30 | 0.70 | 3.61 | — | — | — | — | — | −39.40 |
| Current ratio | 1.01 | 1.15 | 1.28 | 1.60 | 2.37 | 1.95 | 2.08 | 2.69 | 3.88 | 4.43 |
| Quick ratio | 0.84 | 1.03 | 1.11 | 1.26 | 1.93 | 1.53 | 1.71 | 1.69 | 3.50 | 4.07 |
| Interest coverage | -5.6 | -10.6 | -14.3 | -9.7 | -78.3 | -24.2 | -37.7 | -37.7 | -43.9 | -13.5 |
| Working capital | $315,348 | $4.8M | $7.7M | $17.3M | $26.4M | $24.3M | $26.0M | $47.1M | $51.0M | $50.8M |
| Invested capital | $23.6M | $25.5M | $29.7M | $37.5M | $31.8M | $41.5M | $44.4M | $39.6M | $23.6M | $27.1M |
| Tangible asset value | $9.6M | $3.7M | $5.7M | $4.5M | $17.8M | $17.9M | $19.3M | $21.1M | $42.5M | $51.0M |
| Net current asset value | −$15.2M | −$16.6M | −$16.8M | −$11.1M | $3.8M | $379,681 | −$3.3M | $17.7M | $39.4M | $45.3M |
| Graham net-net per share | −$1.67 | −$1.73 | −$1.72 | −$1.54 | −$0.37 | −$0.67 | −$0.97 | −$0.07 | $1.91 | $2.34 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $135,405 | — | $56.0M | $0 | $0 |
| Share buybacks (net) | $263,478 | $579,049 | $740,533 | $1.1M | $1.4M | $1.9M | $3.5M | $2.9M | $3.7M | $2.5M |
| Dividends + buybacks / free cash flow | 5.4% | — | 13.1% | 16.5% | 23.2% | 60.2% | 124.4% | — | — | — |
| Capex / revenue | 0.2% | 0.5% | 1.1% | 4.9% | 1.0% | 5.6% | 0.7% | 10.5% | 3.6% | 6.5% |
| Capex / operating cash flow | 2.0% | — | 7.4% | 24.5% | 5.6% | 39.0% | 8.1% | 137.3% | — | 374.2% |
| Capex / depreciation | 0.02 | 0.03 | 0.08 | 0.39 | 0.08 | 0.45 | 0.06 | 1.43 | 0.56 | 0.89 |
| Stock-based compensation / revenue | 0.9% | 0.8% | 0.9% | 1.1% | 2.1% | 2.8% | 4.3% | 3.3% | 3.6% | 2.6% |
| R&D / revenue | 12.5% | 12.7% | 14.8% | 15.9% | 15.8% | 15.4% | 20.0% | 18.0% | 9.5% | 9.7% |
| SG&A / revenue | 69.7% | 74.3% | 73.6% | 63.9% | 68.9% | 66.7% | 73.4% | 75.3% | 76.6% | 70.0% |
| Efficiency | ||||||||||
| Days sales outstanding | 117.4 | 103.4 | 105.8 | 87.1 | 97.7 | 98.6 | 83.3 | 72.7 | 69.7 | 74.1 |
| Days of inventory on hand | 279.9 | 238.6 | 435.4 | 366.1 | 394.9 | 411.5 | 902.5 | 855.0 | 299.8 | 295.3 |
| Days payables outstanding | 889.1 | 774.6 | 747.8 | 409.5 | 477.2 | 493.3 | 518.6 | 496.5 | 421.3 | 334.3 |
| Cash conversion cycle (days) | -491.8 | -432.6 | -206.6 | 43.7 | 15.4 | 16.8 | 467.3 | 431.2 | -51.8 | 35.1 |
| Receivables turnover | 3.11 | 3.53 | 3.45 | 4.19 | 3.74 | 3.70 | 4.38 | 5.02 | 5.23 | 4.93 |
| Payables turnover | 0.41 | 0.47 | 0.49 | 0.89 | 0.76 | 0.74 | 0.70 | 0.74 | 0.87 | 1.09 |
| Inventory turnover | 1.30 | 1.53 | 0.84 | 1.00 | 0.92 | 0.89 | 0.40 | 0.43 | 1.22 | 1.24 |
| Asset turnover | 0.58 | 0.48 | 0.45 | 0.47 | 0.40 | 0.37 | 0.32 | 0.40 | 0.44 | 0.36 |
| Average receivables | $14.3M | $10.7M | $11.5M | $10.0M | $9.6M | $10.1M | $7.9M | $8.1M | $7.9M | $6.7M |
| Average payables | $16.2M | $14.0M | $12.4M | $10.2M | $11.5M | $11.7M | $10.5M | $10.0M | $8.5M | $5.5M |
| Average inventory | $5.1M | $4.3M | $7.2M | $9.1M | $9.5M | $9.8M | $18.3M | $17.3M | $6.1M | $4.8M |
| Intangibles / total assets | 19.4% | 25.0% | 28.8% | 33.9% | 29.4% | 30.1% | 30.4% | 30.6% | 23.0% | 23.7% |
Computed from CPIX's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CPIX valuation and financial ratios
Cumberland Pharmaceuticals earned a return on equity of −11.9% and a return on invested capital of −9.0% in fiscal 2025. It ended the year with $10.2 million of debt and $11.4 million in cash and short-term investments, a net cash position of $1.3 million. It returned $0.3 million to shareholders: $0 in dividends and $0.3 million in share buybacks, 5% of free cash flow. The share count fell 7.9% from 16.2M to 15.0M over 9 years.
See the CPIX income statement, the CPIX chart for price history, or the CPIX stock overview for the latest quote and news.
CPIX key metrics FAQ
What is Cumberland Pharmaceuticals's EV/EBITDA?
Cumberland Pharmaceuticals's enterprise value was 19.7 times EBITDA at the end of fiscal 2025 (enterprise value $58.3 million, EBITDA $3.0 million); the current EV/EBITDA is 40.9.
What is Cumberland Pharmaceuticals's return on equity?
Cumberland Pharmaceuticals's return on equity (ROE) was −11.9% in fiscal 2025: net income of -$2.8 million on average shareholders' equity of $23.9 million.
What is Cumberland Pharmaceuticals's ROIC?
Cumberland Pharmaceuticals's return on invested capital was −9.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Cumberland Pharmaceuticals have?
Cumberland Pharmaceuticals had total debt of $10.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.41 and more cash than debt.
Does Cumberland Pharmaceuticals buy back its shares?
Yes. Cumberland Pharmaceuticals spent $0.3 million on net share repurchases in fiscal 2025 Shares outstanding changed +6.4% over the year, to 15.0M..
What is Cumberland Pharmaceuticals's free cash flow yield?
Cumberland Pharmaceuticals generated $4.8 million of free cash flow in fiscal 2025, a free cash flow yield of 8.1% on its market value at year-end ($59.5 million).
What is Cumberland Pharmaceuticals's current ratio?
Cumberland Pharmaceuticals's current ratio was 1.01 at the end of fiscal 2025: current assets were 1.01 times current liabilities.